Boston Life Sciences Names Kenneth L. Rice Jr. as Chief Financial Officer

Peter Savas, BLSI's Chairman and CEO, commented, "I am pleasedthat Ken has joined BLSI's executive management team. Ken'srelationships in the life sciences market coupled with his expertisein finance, commercial development, corporate governance and businesslaw will help us achieve our business plan."

Savas went on to say, "We thank Joe Hernon for his contributionsto BLSI throughout the last eight years. Joe's financial andadministrative efforts played an important role in BLSI's earlydevelopment. For the past nine months he has worked diligently with meto successfully restructure the capitalization of the Company. Weappreciate his continued assistance in the near term to ensure asmooth transition."

Mr. Rice brings over 25 years of experience in life sciencesrelated businesses. Most recently, Mr. Rice served as V.P., ChiefFinancial Officer and Chief Commercial Officer of AderisPharmaceuticals, a privately-held biopharmaceutical company. Mr. Ricepreviously held executive positions with MacroChem Corporation,Pentose Pharmaceuticals, Unisyn Technologies, Zymark Corporation andMillipore Corporation. Mr. Rice earned his LLM Taxation from BostonUniversity Law School, his Juris Doctor Cum Laude from SuffolkUniversity Law School and his MBA and BS/BA from Babson College.

Boston Life Sciences, Inc. (BLSI) is a biotechnology companyprimarily focused in the research and clinical development ofbiopharmaceutical products for the diagnosis and treatment of centralnervous system, or CNS, diseases.

Statements in this press release regarding management's futureexpectations, beliefs, goals, plans or prospects may constituteforward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. The Company's actual resultscould differ materially from those stated or implied inforward-looking statements due to a number of factors, including thosefactors contained in the Company's Quarterly Report on 10-Q for thequarter ended March 31, 2005, filed with the Securities and ExchangeCommission under the section "Risk Factors," as well as otherdocuments that may be filed by Boston Life Sciences from time to timewith the Securities and Exchange Commission. As a result of suchrisks, the Company's actual results may differ materially from theresults discussed in or implied by the forward-looking statementscontained herein. Forward-looking statements include statementsregarding Boston Life Sciences' expectations, beliefs, intentions orstrategies regarding the future and can be identified byforward-looking words such as "anticipate," "believe," "could,""estimate," "expect," "intend," "may," "should," "will" and "would" orsimilar words. The Company undertakes no obligation to update orrevise any forward-looking statements, whether as a result of newinformation, future events or otherwise.

Our logo, trademarks, and service marks are the property of BostonLife Sciences, Inc. All other trade names, trademarks, or servicemarks are property of their respective owners and are not the propertyof Boston Life Sciences, Inc.